Grünenthal Innovative Medicines Unit
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. We are an entrepreneurial specialist delivering true benefits to patients. Grünenthal is a fully integrated R&D company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients. By sustainably investing in R&D above the industrial average, we are committing to innovation in order to treat unmet medical needs and bring value-adding products to markets. The Innovative Medicines Unit (IMU) is Grünenthal’s vehicle to take collaborative projects from late discovery through early clinical development. It brings companies, academia, innovative service providers and other experts together to drive innovation forward. The IMU – Leiden Hub enables Grünenthal to engage even more effectively in networked R&D by building strong alliances and partnerships.